This is the authors' abstract. We don't add key points for this paper.
In this last issue of 2017, we're celebrating the 50th anniversary of The FEBS Journal. This Editorial considers how the journal has grown and changed from volume 1, issue 1 and outlines our exciting plans for the future. In this issue, we're celebrating the 50th anniversary of The FEBS Journal. But – we'll let you in on a little secret here – the journal is actually over 100 years old. The FEBS Journal started life in 1906 as the German-language journal Biochemische Zeitschrift. In April 1966, the Federation of European Biochemical Societies (FEBS), the German Gesellschaft für Biologische Chemie and the publisher Springer-Verlag reached an agreement wherein FEBS would continue publishing Biochemische Zeitschrift under a different name: European Journal of Biochemistry. The editorial board, helmed by Editor-in-Chief Claude Liébecq, first convened in Heidelberg in July 1966, the first submission was received in September 1966, and the first issue of European Journal of Biochemistry appeared on 1 March 1967 [1] (Fig. 1). In 2005, European Journal of Biochemistry was renamed The FEBS Journal. The journal has come far since volume 1, issue 1 (see Fig. 2 for a timeline of notable events). Initially, manuscripts could be submitted in any of three languages – German, French or English – indeed, the first submission was in German. However, by 1970, most submissions were in English [1]. The journal published just over 150 manuscripts in its first year, with the first issue containing 18 papers. Today, we count over 32 000 manuscripts in the journal's archives and publish around 320 manuscripts each year (Fig. 3). Review articles began appearing in the journal's pages in 1986, with a review titled ‘Micellar enzymology’ by Ilya Berezin and colleagues that focused on ‘experimental approaches to modelling the enzymatic function of biological membranes’ [2]. Reviews have since made up an increasingly important part of the journal's pages and really came into their own under current Editor-in-Chief Seamus Martin. He developed and launched several new review types – State-of-the-Art Reviews, Discovery-in-Context Reviews, Structural Snapshots and Viewpoints – that are among the journal's most highly cited and downloaded content. In its 50-year history with FEBS, the journal has been led by four Editors in Chief. After 22 years with the journal, Claude Liébecq passed the editorial baton to Philipp Christen in 1988. This coincided with the relocation of the journal's editorial office from Liège, Belgium, to Zürich, Switzerland. Richard Perham took the reins in 1998 as the journal's third Editor-in-Chief and moved the editorial office from Zürich to Cambridge, UK (where it remains today). In 2014, Seamus Martin became the journal's fourth Editor-in-Chief – and it is safe to say that the publishing landscape that we currently navigate looks a lot different now compared with 50 years ago. Each Editor-in-Chief has presided over an editorial board and advisory board of active and well-respected scientists representing different fields in the molecular life sciences. The first board comprised 21 scientists, with Sir Hans Krebs assuming the role of Honorary Chairman. The board has expanded and contracted over the years to meet the demands facing the journal – such as changes to the numbers of submissions, research areas, and demographics of our authors and readers. Today, the journal's editorial board comprises 28 members from diverse fields, who each bring unique viewpoints and spirited discussions to the manuscripts that they handle (not to mention our annual editorial board meeting). Several of our board members (Alex Wlodawer, Kevin Ryan, Pura Muñoz-Cánoves and Colin Adrain) are also involved in commissioning review content, and we are very grateful for their sterling efforts on behalf of the journal. No doubt many of our readers will remember a time when multiple hard copies of manuscripts and associated figures (labelled on the back with the first author's name and indicating which way was up) were sent to journals for review and publication. Indeed, the process of printing out a paper for submission to a journal and mailing it to the journal's editorial offices used to be quite an ordeal that the internet age has completely eliminated. The journal's first computer programme for tracking submissions was developed in 1998 by editorial secretary Sarah Meredith, and at the time, authors hotly anticipated a FAX from the journal's editorial office conveying positive news [1]. We moved to an online submission system in 2002 and have, for better or worse, stayed with the same submission system since then: ScholarOne Manuscripts. Most communication happens through e-mail these days, of course, though we occasionally field phone calls from authors and look forward to meeting authors, referees and readers in person at conferences and lab visits. Technological changes have occurred on the publishing side, too. In 2002, manuscripts that had been accepted for publication, copyedited and typeset began to be published online before formal inclusion in one of the journal's issues – this was known as ‘early view’ online publication and helped ensure that research was rapidly disseminated. However, in 2010, we went a step further by publishing the accepted (i.e. not copyedited or typeset) version of an article online just 3–4 days after formal acceptance. In part because of its growing online presence, the journal adopted online-only publishing in 2013. A single volume of the journal is printed each year and delivered to the editorial office in Cambridge (Fig. 4). Because the journals archives are online, we do not routinely revisit these physical back issues, though every now and then it is nice to dust off and flip through an old volume and marvel at how far molecular biology has come in such a short time. The journal website received a major overhaul in 2016 coinciding with the launch of FEBS Press, which consolidated all of the FEBS journals (The FEBS Journal, FEBS Letters, Molecular Oncology and FEBS Open Bio) onto the same publishing platform, published by Wiley. The transition to FEBS Press was quite a complex process, involving several publishers, protracted and detailed negotiations and many long meetings, but all managed with aplomb by László Fésüs who oversees all of the FEBS Press journals in his role as Chairman of the FEBS Publications committee. Our new website has a fresh look, is easy to navigate and has some very useful features such as the ability to view forthcoming papers, our most highly downloaded content, or the most highly cited papers in different time windows, all with the click of a tab. The creation of FEBS Press also brings new coherence and focus to all of the journals published by FEBS, enabling closer cooperation between the different journal editorial teams, and the development of cross-journal initiatives. Changes outside of our office doors have also affected how we work. Although the journal has always considered manuscripts that were previously (or concurrently) posted to a recognised preprint repository, we made this policy official in 2016 with an amendment to our author guidelines. Also in 2016, we began offering authors a home for their large unstructured datasets via an automated link with the data-sharing site figshare. To date, seven authors have availed themselves of this link and you can browse, download and reuse their raw data at https://wiley.figshare.com/febsj. Although all primary research articles are freely available 1 year after publication (and all review content is available for free immediately upon publication), the journal also offers authors the option to make their work open access. In 2012, just five authors elected to do so, but in 2016, 34 open-access manuscripts were published. [The first] volume also contained the description of the ‘protein sequenator’, by P. Edman and G. Begg. We owed this favour to a trip Samuel M. Rapoport had made to Australia a few months before; he had visited the St-Vincent's School of Medical Research in Melbourne and convinced Edman to offer his contribution for the first issue of the journal. This soon became one of Current Contents’ ‘citation classics’. It helped establish the reputation of the journal at once. Indeed, Edman and Begg's paper has been cited 3043 times [4]. Other historical methodology papers have also attracted wide attention, such as Bonner and Laskey's 1974 paper entitled ‘Film detection method for tritium-labeled proteins and nucleic acids in polyacrylamide gels’ (9297 citations) [5], or Pelham and Jackson's 1976 paper entitled ‘Efficient messenger-RNA-dependent translation system from reticulocyte lysates’ (3893 citations) [6]. As the years rolled on, however, the papers tended to shift from the methodological to the biological. The journal published the first descriptions of 2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine (olomoucine) [7] and roscovitine [8] as inhibitors of cyclin-dependent kinases and cell-cycle progression in 1994 and 1997, respectively. In these papers, Meijer and colleagues noted that the above-mentioned compounds blocked cell-cycle progression of Xenopus oocytes. A neat coda to these early papers was published more than 15 years later by Jeon and Lee, who showed that morpholino-directed depletion of Aurora A kinase in zebrafish activated the spindle assembly checkpoint and induced mitotic arrest in vivo [8]. The techniques and models might have evolved, but it is thrilling to see the same sorts of fundamental biological insights into cell-cycle regulation reported across the decades. Indeed, many fundamental early discoveries on proteins that have since gained wide recognition were published in The FEBS Journal. 1986 was a particularly notable year for this, as the journal published papers on p53 [9] and protein kinase C (PKC) [10]. By our count, there were 183 papers on p53 before 1986, and an astonishing 87 663 in the 30 years since. Similarly, just 23 papers on PKC were published before 1986, whereas 32 227 papers have been published in the intervening years. One highlight in 1990 was a manuscript by Nishida and colleagues describing the identification of a MAP kinase in PC12 cells [11] – this landmark paper was among the early efforts to understand signal transduction downstream of EGF and NGF. These early signalling papers formed a foundation that enabled subsequent research in more biologically relevant settings. Indeed, in recent years, signalling and cancer have gone hand-in-hand in the journal [12-18], as have papers investigating signalling in the context of immune responses and inflammation [19-22]. Strong papers reporting insights into the nature of crosstalk between apoptosis and autophagy [23], as well as the regulation of apoptosis [24, 25], autophagy [26-28] and necroptosis [29, 30], have all found homes in the journal's pages. The journal's interest in cell death was recognised in 2016, with the comprehensive and excellent Special Issue on Cell Death Control, coordinated by Jerry Chipuk and Editor-in-Chief Seamus Martin [31-44]. But it is not all life and (cell) death within the journal's pages – structural studies have always been an important focus for the journal. This long-standing interest is revealed by excellent structural papers on proteins involved in neurodegenerative diseases [45-48], as well as early structural insights into cell adhesion [49-51]. More recently, the journal has published structural data that might help inform drug discovery, including structures of colchicine-binding site inhibitors in complex with tubulin [52], SYK in complex with new inhibitors [53], and the Mycobacterium tuberculosis ketol-acid reductoisomerase [54] and penicillin-binding protein PonA1 [55]. However, the tides seem to be shifting so that technology-driven papers are again rising in profile. In 2005, the year before Fire and Mello won their Nobel Prize in Physiology or Medicine for their discovery of RNA interference, the journal published a report on the ‘systematic search for interspecies orthologues of miRNA precursors’ from Michel Weber [56]. The interest in miRNAs has never waned – these papers consistently rank among the journal's most highly cited and downloaded content. However, CRISPR-mediated gene editing technology is proving to be just as exciting. The first CRISPR papers appeared in 2014 [57, 58], with a fantastic review published at the end of 2014 [59] that brought many new potential authors and readers to the journal and resulted in a feed-forward loop of wonderful papers and reviews [60-64]. The interest in the topic was so great that, in 2016, John Doench coordinated a Special Issue devoted to CRISPR/Cas9-mediated gene editing [65-74]. In recent years, we have introduced several new article types to add diversity to our content, and these are proving very popular with our readership. ‘State-of-the-Art’ reviews, which are written by leading experts in their fields, have become our flagship review format and we have published over 100 of these since 2014. The latter reviews are very heavily downloaded and cited and are provided free to view from the moment of publication. The FEBS Journal has a long association with the structural biology community and ‘Structural Snapshots’, which we launched in 2015, focus on important structures that are novel or have important biological or therapeutic relevance. Our ‘Viewpoints’ series, also introduced in 2015, deal with novel hypotheses, ideas or views on current topics. These articles are typically provocative or controversial and we have published some highly notable contributions in this series thus far that have generated considerable discussion and feedback. One of our favourite new article types, the first of which we published in 2015, are called ‘Discoveries-in-Context’ perspectives. These are written by scientists who have made major breakthroughs in their areas and discuss their personal views and insights on how their breakthrough occurred, what was known at the time, how the discovery was made, and so on. ‘Discoveries-in-Context’ articles provide a fascinating perspective on how science is done and reveal the often serendipitous and unpredictable nature of science. To offer guidance and career support to the next generation of scientists, we introduced ‘Words-of-Advice’ articles in 2016, which are also proving very popular with our readership. These articles cover topics such as ‘how to write a scientific paper’, ‘scientific career paths’, ‘how to avoid common pitfalls of manuscript and figure preparation’, and ‘how to write a grant or fellowship application’. And finally, we will also introduce a new article type in 2018, called ‘A Guide to….’, that will address methodology or terminology in cutting edge fields (more about this below). So, what will the next 50 years hold? We know that scientific publishing won't bear much of a resemblance to the current process as preprints and postpublication review rise in importance and prominence. We certainly hope that there will always be a place for society journals such as ours that exist to serve and support scientists, or as the FEBS Press strapline reads: ‘science publishing by scientists’. However, ‘hope’ is not an acceptable long-term survival strategy in the days of megajournals and predatory publishers, and we focus our efforts on providing the best possible service for our authors and readers – by eliminating page and colour figure charges, offering all review content for free from the moment of publication, providing fast peer review and limiting the number of rounds of revisions, and capping each issue at a maximum of 10 primary research papers to ensure that every paper that we publish is highly visible. We are also continuously striving to improve the look and reach of every paper we publish by working closely with authors of accepted manuscripts to enhance the presentation of their figures and key message of their paper. This year, we've also introduced a figure-checking step for all accepted manuscripts to ensure that the data published in The FEBS Journal is robust and meets the highest standards of integrity. At this point, we have also mapped out five potential Special Issues to be published in 2018 and 2019 – eagle-eyed readers might have already spotted the first few reviews in our Cancer and Inflammation Special Issue, which should be published early in 2018. We are also developing additional new article types and features that should come online within the next year as well. As one example of this, we will launch a new type of article called ‘A Guide to…’ that will provide cutting edge information concerning fast-moving fields where the terminology is complex and evolving (e.g. microRNA targets, cytokines/chemokines) or methodologies that are used to explore a pathway or process (ER stress, cell death, autophagy, cell cycle). We are also travelling more than ever to meet our authors and readers at conferences and lab visits and solicit feedback on the journal and publishing processes more generally. Regardless of what the future holds, we thank you, our authors and readers, for being part of the past 50 years of the journal, and look forward to the journey ahead. Why not become part of our next 50 years by submitting a manuscript to us in the year ahead?
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Chenette et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: